A biotech was planning to launch its first gene therapy, a hemophilia treatment. They wanted to gain a greater understanding of the key stakeholders, health care systems, and pre-empt likely challenges in the gene therapy market to best prepare for a successful launch.
- Designed a mapping template to identify innovative pricing and access initiatives, and potential gene-therapy and healthcare policy developments in The Netherlands, Belgium, Austria, Switzerland, Poland, Romania and Greece
- Identified commonalities between countries, and areas that required action for a successful hemophilia gene-therapy launch, to develop country archetypes
- Engaged internal and external stakeholder to understand payer perception of gene therapy, opportunities and challenges, and openness to innovative pricing schemes
- Developed targeted strategies addressing concerns and expectations of the local affiliates and uncovered knowledge and information gaps that needed to be addressed both in the selected countries and the company’s internal team
The global and local teams were able to agree on a coherent message across the organisation as well as engagement priorities. A roadmap was recommended to help the client understand what pragmatic steps were needed to be taken towards launch. This was able to support the global team in identifying areas that need attention and support the company successfully in gene therapy.
Working with P4A really helped us understand the practical steps needed for a successful gene therapy launch.
Global Gene Therapy Lead